GAIHTERSBURG, Md. - Novavax , Inc. (NASDAQ: NASDAQ:NVAX) has announced that its updated Nuvaxovid COVID-19 vaccine, designed to target the JN.1 variant and its lineages, has received Marketing Authorization from the European Commission for individuals aged 12 and older within the European Union (EU). The authorization follows a positive assessment by the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use.
The decision was informed by non-clinical data demonstrating that the updated vaccine, NVX-CoV2705, produces cross-reactivity against several JN.1 lineage viruses. The clinical trials of Novavax's prototype vaccine, NVX-CoV2373, reported common adverse reactions such as headache, muscle and joint pain, and injection site pain and tenderness.
The vaccine is also authorized for emergency use in the United States and aligns with recommendations from the U.S. Food and Drug Administration (FDA), EMA, and the World Health Organization to target the JN.1 lineage for the current season.
Novavax's NVX-CoV2705 is a protein-based vaccine utilizing the company's recombinant nanoparticle technology and Matrix-M adjuvant to enhance the immune response. It is stored between 2° to 8°C, which allows for the use of existing vaccine supply chains.
The vaccine's safety information includes contraindications for individuals with a history of severe allergic reactions to any of its components. It also lists potential risks of myocarditis and pericarditis and advises caution for immunocompromised individuals due to possibly diminished vaccine effectiveness.
Healthcare providers are required to report adverse events to the Vaccine Adverse Event Reporting System (VAERS). The vaccine's Emergency Use Authorization (EUA) in the U.S. will remain valid as long as the COVID-19 EUA declaration is in effect, or until it is revoked.
Novavax is a biotechnology company focused on developing vaccines against infectious diseases, with a portfolio including its COVID-19 vaccine and candidates for COVID-19-Influenza Combination and standalone influenza vaccines.
This news is based on a press release statement from Novavax, Inc.
In other recent news, Novavax has been the focus of several positive analyst notes, with Jefferies maintaining a Buy rating on the company's stock. The firm highlighted Novavax's strong COVID-19 vaccine sales outlook and the potential for growth due to favorable product presentation and logistics. Jefferies also noted that Novavax is on track to meet its revenue guidance for the 2024/2025 season, mirroring the approximately $3 to $5 billion total market seen in the previous season.
Novavax has also seen significant developments in its team, with the appointment of Ruxandra Draghia-Akli, MD, PhD, as its new Executive Vice President and Head of Research & Development. In addition, the company has rolled out an updated COVID-19 vaccine targeting the JN.1 variant across U.S. pharmacies, following Emergency Use Authorization from the U.S. Food and Drug Administration for individuals aged 12 and older.
Financially, Novavax reported a Q2 2024 revenue of $415 million, largely due to a significant partnership with Sanofi (NASDAQ:SNY). The company also anticipates a total revenue of between $700 million and $800 million for the full year 2024. In an effort to reduce costs, Novavax is exploring strategies such as renegotiating or exiting Advance Purchase Agreements for vaccine distribution and considering the sale of its Czech Republic manufacturing facility.
InvestingPro Insights
As Novavax (NASDAQ: NVAX) secures Marketing Authorization for its updated COVID-19 vaccine in the European Union, investors may be keen to understand the company's financial position and market performance. According to InvestingPro data, Novavax's market capitalization stands at $2.09 billion, reflecting its significant presence in the biotechnology sector.
Despite the positive news on vaccine authorization, Novavax faces some financial challenges. An InvestingPro Tip indicates that the company is not profitable over the last twelve months, with a negative operating income of $286.23 million for the same period. This aligns with another tip suggesting that analysts do not anticipate the company will be profitable this year.
However, it's worth noting that Novavax holds more cash than debt on its balance sheet, which could provide some financial flexibility as it continues to develop and market its vaccine portfolio. This strength is particularly important given the company's revenue of $987.67 million in the last twelve months, representing a decline of 38.17% year-over-year.
The stock's performance has been volatile, with a significant 195.02% price increase over the last six months, despite a recent 11.17% drop in the past week. This volatility is consistent with the InvestingPro Tip indicating that Novavax's stock price movements are quite volatile.
For investors seeking a more comprehensive analysis, InvestingPro offers 11 additional tips for Novavax, providing deeper insights into the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.